IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1251-1275 out of 1422.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

Public Release: 22-Feb-2016
Proceedings of the National Academy of Sciences
New 'lipidomics' method could bring fast cancer diagnosis
Researchers have developed a new analytical tool for medical applications and biological research that might be used to diagnose cancer more rapidly than conventional methods. The research has implications for the field of lipidomics, which involves the identification and quantification of cellular lipid molecules, how they interact with other components in cells and their role in biological systems.
National Science Foundation, National Institutes of Health

Contact: Emil Venere
venere@purdue.edu
765-494-4709
Purdue University

Public Release: 22-Feb-2016
Developmental Cell
Cancer in 3-D
Cancer cells don't live on glass slides, yet the vast majority of images related to cancer biology come from the cells being photographed on flat, two-dimensional surfaces. A new high-resolution microscope, presented Feb. 22 in Developmental Cell, now makes it possible to visualize cancer cells in 3-D and record how they are signaling to other parts of their environment, revealing the previously unappreciated biology of how cancer cells functions within living things.

Contact: Joseph Caputo
jcaputo@cell.com
617-397-2802
Cell Press

Public Release: 22-Feb-2016
CA: A Cancer Journal for Clinicians
Cancer statistics for African-Americans, 2016
A new report outlines substantial progress in reducing the mortality gap between blacks and whites for some cancers, while the gap has widened or remained level for two leading cancers
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 22-Feb-2016
Journal of the National Cancer Institute
Are lung cancer survivors getting too many costly scans for no reason? Study suggests so
Once you've made it through lung cancer treatment, you want to make sure you catch it early if it comes back again. But a new study suggests that one approach to watching for a cancer's return is being inappropriately used at many hospitals. And it isn't helping patients survive longer, the research shows.
National Institutes of Health, Agency for Healthcare Research and Quality, American Cancer Society

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 22-Feb-2016
PLOS ONE
Non-destructive technique measures oxygen levels in 3-D cells used for toxicity testing
A non-destructive technique which can measure the concentration and consumption of oxygen in 3-D models of biological cells has been developed by Plymouth University in partnership with pharmaceutical company AstraZeneca.

Contact: Alan Williams
alan.williams@plymouth.ac.uk
44-175-258-8004
University of Plymouth

Public Release: 22-Feb-2016
Cancer
Weight and height during adolescence may impact future risk of developing Non-Hodgkin's lymphoma
A new analysis indicates that higher body weight and taller stature during adolescence increase the risk of developing Non-Hodgkin's lymphoma, a type of cancer of the lymphatic system. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 22-Feb-2016
Journal of the National Cancer Institute
Study shows likely overuse of PET scans to detect recurrence in lung & esophageal cancers
Use of positron emission tomography (PET) showed no association with two-year survival in lung and esophageal cancer patients and may possibly be overused in the hopes of detecting cancer recurrence, according to a study published Feb. 22 in the JNCI: Journal of the National Cancer Institute.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 22-Feb-2016
Leukemia
Researchers pinpoint potential enzyme for T-cell leukemia treatment
For the first time, researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival.
NIH/National Cancer Institute, Leukemia Research Foundation, and others

Contact: Gina DiGravio
ginad@bu.edu
617-638-8480
Boston University Medical Center

Public Release: 22-Feb-2016
Canadian Medical Association Journal
New Canadian recommendation against colonoscopy for routine screening of colorectal cancer
Physicians should screen for colorectal cancer in asymptomatic, low-risk adults aged 50 to 74 years every two years using fecal occult blood testing (FOBT), or flexible sigmoidoscopy every 10 years, rather than colonoscopy, according to a new Canadian guideline from the Canadian Task Force on Preventive Health Care in CMAJ (Canadian Medical Association Journal).
Public Health Agency of Canada, Canadian Institutes of Health Research, Health Canada Canadian Partnership Against Cancer

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116
Canadian Medical Association Journal

Public Release: 22-Feb-2016
European Journal of Oncology Nursing
Research warns about the sleep disturbances in patients with cancer
Researchers from the Hospital Inmaculada ONCOSUR-Granada hospital and the University of Granada prove that sleep problems are very significant among patients with cancer prior to undergoing radiotherapy.

Contact: Gualberto Buela Casal
gbuela@ugr.es
34-958-243-750
University of Granada

Public Release: 22-Feb-2016
Journal of Thoracic Oncology
FDA-approved ALK IHC CDx superior to another IHC assay for patient selection
The US Food and Drug Administration approved VENTANA anti-ALK(D5F3)CDx performed more accurately than another commonly used immunohistochemistry (IHC) assay, based on the use of the 5A4 clone, for the selection of patients eligible to receive ALK tyrosine kinase inhibitor (TKI) treatment.

Contact: Jeff Wolf
Jeff.Wolf@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 22-Feb-2016
Nature Biotechnology
Crafting a better T cell for immunotherapy
T-cell therapy, a form of immunotherapy, involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer. Now, a group of researchers has devised a new approach that could speed and improve this process, using a special, small protein tag that can be used to purify and track the T cells once they have been engineered in the laboratory.
Walker Immunotherapy Fellowship, Fred Hutchinson Cancer Research Center Synergy Technology Fund, National Institutes of Health

Contact: Sandy Van
svan2@fredhutch.org
808-526-1708
Fred Hutchinson Cancer Research Center

Public Release: 22-Feb-2016
TOMOGRAPHY
Using sugar to detect malignant tumors
Ordinary sugar could become a contrast agent of the future for use in magnetic resonance tomography examinations of tumors. Malignant tumors show higher sugar consumption than surrounding tissue.

Contact: Cecilia Schubert
cecilia.schubert@kommunikation.lu.se
46-708-661-383
Lund University

Public Release: 21-Feb-2016
Oncogene
New genetic cause of gastric and prostate cancer identified
Researchers at Hiroshima University have opened the door to finding a new class of cancer-causing genetic variations. Using a combination of pre-existing electronic databases and their own experiments with cancerous and healthy cells, researchers linked stomach (gastric) and prostate cancer to a specific type of DNA called transcribed-ultraconserved regions (T-UCRs). This approach will likely reveal more links between T-UCRs and other cancers in the future.
Education, Culture, Science, Sports and Technology of Japan, Ministry of Health, Labor and Welfare of Japan, National Institute of Biomedical Innovation, National Cancer Center Research and Development Fund

Contact: Norifumi Miyokawa
pr-research@office.hiroshima-u.ac.jp
Hiroshima University

Public Release: 19-Feb-2016
Cell Reports
Scientists discover secret to promising new cancer drug
Australian researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work -- paving the way for improving the future of cancer treatment.
National Health and Medical Research Council, Leukemia and Lymphoma Society, Cancer Council Victoria, Leukaemia Foundation of Australia, Victorian Cancer Agency, Victorian Government Operational Infrastructure Support Scheme

Contact: Arunee Wilson
wilson.a@wehi.edu.au
047-871-4757
Walter and Eliza Hall Institute

Public Release: 19-Feb-2016
Science
Shape-shifting engineered nanoparticles for delivering cancer drugs to tumors
University of Toronto engineering professor Warren Chan has spent the last decade figuring out how to deliver chemotherapy drugs into cancerous tumors -- and nowhere else. Now his lab has designed a set of nanoparticles attached to strands of DNA that can change shape to gain access to diseased tissue.

Contact: Marit Mitchell
marit.mitchell@utoronto.ca
416-978-4498
University of Toronto Faculty of Applied Science & Engineering

Public Release: 19-Feb-2016
Scientific Reports
Researchers find link between death of tumor-support cells and cancer metastasis
NIH-funded researchers at Massachusetts General Hospital find surprising link between the death of tumor-support cells and an increased risk of cancer metastasis in mice.
Shriners Hospitals for Children, National Institutes of Health, Massachusetts General Hospital Fund for Medical Discovery

Contact: Jessica Meade
NIBIBpress@mail.nih.gov
301-496-3500
NIH/National Institute of Biomedical Imaging & Bioengineering

Public Release: 19-Feb-2016
Scientific Reports
Tumor heterogeneity resolved: A new technology isolates pure tumor cells from FFPE samples
A new study, published last week by Scientific Reports, presents a revolutionary method to isolate 100 percent pure tumor and stromal cell populations from minute formalin fixed, paraffin embedded specimens using the DEPArrayTM technology. Scientists at Silicon Biosystems, a Bologna- and San Diego-based biotech company, demonstrated that DEPArrayTM sorting allows downstream analysis of tumor genetic characteristics via next generation sequencing with unprecedented precision.

Contact: Elena Bevilacqua
EBevilacqua@siliconbiosystems.com
39-347-234-5559
SiliconBiosystems

Public Release: 19-Feb-2016
PLOS ONE
Eye movement affected in former childhood cancer patients
Nowadays, the lives of the majority of all children with cancer can be spared. However, the cure for the disease comes with a price: some of the survivors will suffer long-term injury from the treatment. A study from Lund University in Sweden now shows that commonly used chemo toxins impair the eyesight in childhood cancer survivors in a way that indicates an impact on the central nervous system.

Contact: Cecilia Schubert
cecilia.schubert@kommunikation.lu.se
46-708-661-383
Lund University

Public Release: 19-Feb-2016
Neuro-Oncology
Biochemical alteration responsible for brain tumor resistance identified
Researchers from the Institute of Neuroscience (INc) of the Universitat Autonoma de Barcelona (UAB) have identified the biochemical and molecular alteration that causes resistance to radiotherapy and chemotherapy in the glioblastoma , the most aggressive of brain tumors. This finding could in future enable new, more effective therapies to be designed.

Contact: Victor J. Yuste
Victor.yuste@uab.cat
34-935-813-762
Universitat Autonoma de Barcelona

Public Release: 19-Feb-2016
Journal of Clinical Investigation
Gene therapy: T cells target mutations to fight solid tumors
An international research team from the Max Delbrück Center for Molecular Medicine (MDC) and the Charité (partners in the Berlin Institute of Health, BIH), the Humboldt University Berlin and the University of Chicago has successfully modified immune cells to recognize and specifically target tumor cells in mice. Cancer treatments based on the findings would likely have fewer side effects than standard therapies currently in use.
Berlin Institute of Health, German Research Foundation

Contact: Josef Zens
josef.zens@mdc-berlin.de
49-309-406-2118
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Public Release: 19-Feb-2016
Bladder Cancer
Researchers make progress in genomic classification of bladder cancers
Now, it is possible to extract the DNA or RNA from cancer cells and establish a classification according to the type and quantity of mutations, active and inactive genes, and other molecular characteristics. An article in the current issue of Bladder Cancer reports the results of a consensus meeting of experts in the field and describes the recent efforts to classify bladder cancers.

Contact: Daphne Watrin
d.watrin@iospress.nl
0031-206-883-355
IOS Press

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Study determines key recurrence detection time for oropharyngeal cancer
For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
No survival advantage of induction chemo over CRT for locally advanced head and neck cancer
Head and neck cancer patients who receive induction chemotherapy (IC; chemotherapy administered prior to radiation therapy) rather than the standard treatment of concurrent chemoradiation do not benefit from increased survival rates and are less likely to receive a full course of radiation, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Public Release: 18-Feb-2016
2016 Multidisciplinary Head and Neck Cancer Symposium
Study links health insurance status and head and neck cancer diagnoses, outcomes
Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Contact: Liz Gardner
liz.gardner@astro.org
703-286-1600
American Society for Radiation Oncology

Showing releases 1251-1275 out of 1422.

<< < 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 > >>

  Search News Releases

     

 

EurekAlert!